BR112017005266B1 - Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende - Google Patents

Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende Download PDF

Info

Publication number
BR112017005266B1
BR112017005266B1 BR112017005266-0A BR112017005266A BR112017005266B1 BR 112017005266 B1 BR112017005266 B1 BR 112017005266B1 BR 112017005266 A BR112017005266 A BR 112017005266A BR 112017005266 B1 BR112017005266 B1 BR 112017005266B1
Authority
BR
Brazil
Prior art keywords
compound
mmol
aliphatic
int
certain embodiments
Prior art date
Application number
BR112017005266-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017005266A2 (pt
Inventor
Matthew David Alexander
Claudio Chuaqui
John Malona
Joseph John Mcdonald
Yike Ni
Deqiang Niu
Russell C. Petter
Juswinder Singh
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of BR112017005266A2 publication Critical patent/BR112017005266A2/pt
Publication of BR112017005266B1 publication Critical patent/BR112017005266B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112017005266-0A 2014-09-17 2015-09-16 Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende BR112017005266B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US62/051,788 2014-09-17
US201562199927P 2015-07-31 2015-07-31
US62/199,927 2015-07-31
PCT/US2015/050495 WO2016044463A2 (en) 2014-09-17 2015-09-16 Mk2 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
BR112017005266A2 BR112017005266A2 (pt) 2017-12-12
BR112017005266B1 true BR112017005266B1 (pt) 2022-11-01

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017005266-0A BR112017005266B1 (pt) 2014-09-17 2015-09-16 Compostos inibidores de mk2 e composição farmaceuticamente aceitável que os compreende

Country Status (30)

Country Link
US (5) US9458175B2 (cg-RX-API-DMAC7.html)
EP (2) EP3912981A1 (cg-RX-API-DMAC7.html)
JP (3) JP6556225B2 (cg-RX-API-DMAC7.html)
KR (1) KR102457848B1 (cg-RX-API-DMAC7.html)
CN (1) CN106998692B (cg-RX-API-DMAC7.html)
AU (1) AU2015317741B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017005266B1 (cg-RX-API-DMAC7.html)
CA (1) CA2961607C (cg-RX-API-DMAC7.html)
CL (1) CL2017000576A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017003279A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124215T1 (cg-RX-API-DMAC7.html)
DK (1) DK3193611T3 (cg-RX-API-DMAC7.html)
EA (1) EA037299B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17023281A (cg-RX-API-DMAC7.html)
ES (1) ES2874561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210529T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054347T2 (cg-RX-API-DMAC7.html)
IL (1) IL251051B (cg-RX-API-DMAC7.html)
LT (1) LT3193611T (cg-RX-API-DMAC7.html)
MA (1) MA40534B1 (cg-RX-API-DMAC7.html)
MX (2) MX373341B (cg-RX-API-DMAC7.html)
PL (1) PL3193611T3 (cg-RX-API-DMAC7.html)
PT (1) PT3193611T (cg-RX-API-DMAC7.html)
RS (1) RS62017B1 (cg-RX-API-DMAC7.html)
SA (1) SA517381115B1 (cg-RX-API-DMAC7.html)
SG (2) SG11201701861RA (cg-RX-API-DMAC7.html)
SI (1) SI3193611T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100311T1 (cg-RX-API-DMAC7.html)
TW (1) TWI744217B (cg-RX-API-DMAC7.html)
WO (1) WO2016044463A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
AU2018236286B2 (en) * 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
JP2020511468A (ja) * 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Mk2阻害剤の重水素化アナログおよびその使用
EP3596086A4 (en) * 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
EP3596084A4 (en) * 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
JP7692353B2 (ja) * 2018-10-02 2025-06-13 ディスク・メディスン,インコーポレイテッド マトリプターゼ2阻害剤及びその使用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
US12594277B2 (en) 2020-02-14 2026-04-07 Salk Institute For Biological Studies Macrocyclic ULK1/2 inhibitors
WO2021163633A1 (en) * 2020-02-14 2021-08-19 Salk Institute For Biological Studies Mono and combination therapies with ulk1/2 inhibitors
WO2021178449A1 (en) * 2020-03-02 2021-09-10 Washington University Compositions and methods for the treatment of pancreatic cancer
WO2022020562A1 (en) * 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders
CA3201774A1 (en) * 2020-11-12 2022-05-19 Akttyva Therapeutics, Inc. Mk2 activating compounds for use in treating vascular leak and endothelial barrier disorders
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
EP4079855A1 (en) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Compound and method for the prophylaxis and treatment of leukemia
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
WO2024044731A1 (en) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
US12668598B2 (en) 2022-10-27 2026-06-30 Bristol-Myers Squibb Company MK2 inhibitors and uses thereof
KR20250139398A (ko) * 2023-02-07 2025-09-23 셀진 코포레이션 Mk2 키나제의 분해제로서 유용한 화합물 및 조성물
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy
CN121368484A (zh) * 2023-06-26 2026-01-20 深圳信立泰药业股份有限公司 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
BR0317430A (pt) 2002-12-20 2005-10-25 Pharmacia Corp Compostos inibidores de quinase-2 de proteìna ativada por quinase de proteìna ativada por mitógeno
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2010533674A (ja) 2007-07-16 2010-10-28 ノバルティス アーゲー Mk2阻害剤として有用なヘテロ環式化合物
CA2703203C (en) 2007-10-22 2015-12-15 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN112029513B (zh) 2012-02-22 2024-02-23 默克专利股份有限公司 液晶介质
EP2832734A4 (en) * 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
EP2872144A4 (en) * 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
CN104981791A (zh) * 2012-09-24 2015-10-14 克莱尔蒙特·斯皮德 移动发送方控制的数据访问和数据删除方法和系统
WO2014050779A1 (ja) * 2012-09-25 2014-04-03 第一三共株式会社 Gsk3阻害剤と抗dr5抗体の組み合わせ
US10138256B2 (en) * 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2015050957A2 (en) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Treatments for systemic lupus erythematosus
US10512651B2 (en) 2014-08-25 2019-12-24 Stc.Unm Inhibition of MK2 in the treatment of cancer
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
EP3596086A4 (en) 2017-03-16 2020-12-16 Celgene CAR LLC MK2 INHIBITORS, THEIR SYNTHESIS AND THEIR INTERMEDIARIES
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
AU2018236286B2 (en) 2017-03-16 2022-02-17 Bristol-Myers Squibb Company Forms and compositions of a MK2 inhibitor
EP3596084A4 (en) 2017-03-16 2020-12-23 Celgene CAR LLC 9,10,11,12-TETRAHYDRO-8H- [1,4] DIAZEPINO [5 ', 6': 4,5] THIÉNO [3,2-F] QUINOLIN-8-ONE COMPOUNDS AND THEIR USES
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Mk2阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
WO2022020562A1 (en) 2020-07-24 2022-01-27 Bristol-Myers Squibb Company Methods of treating acute respiratory disorders

Also Published As

Publication number Publication date
WO2016044463A3 (en) 2016-09-01
WO2016044463A2 (en) 2016-03-24
AU2015317741A1 (en) 2017-04-20
IL251051A0 (en) 2017-04-30
AU2015317741B2 (en) 2020-01-16
SA517381115B1 (ar) 2021-03-09
IL251051B (en) 2019-11-28
MA40534B1 (fr) 2021-04-30
SI3193611T1 (sl) 2021-08-31
JP2022078315A (ja) 2022-05-24
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
JP7375072B2 (ja) 2023-11-07
MA40534A (fr) 2016-03-24
US11584757B2 (en) 2023-02-21
EP3193611A4 (en) 2018-02-28
EA037299B1 (ru) 2021-03-05
CO2017003279A2 (es) 2017-09-29
TWI744217B (zh) 2021-11-01
EA201790380A1 (ru) 2017-08-31
US9458175B2 (en) 2016-10-04
HUE054347T2 (hu) 2021-08-30
JP2019194236A (ja) 2019-11-07
TW201617351A (zh) 2016-05-16
KR20170063734A (ko) 2017-06-08
US20170114073A1 (en) 2017-04-27
EP3193611A2 (en) 2017-07-26
EP3912981A1 (en) 2021-11-24
NZ730603A (en) 2024-02-23
CA2961607A1 (en) 2016-03-24
CN106998692B (zh) 2020-09-08
LT3193611T (lt) 2021-08-25
US20210053984A1 (en) 2021-02-25
CN106998692A (zh) 2017-08-01
SMT202100311T1 (it) 2021-07-12
MX2017003359A (es) 2017-11-22
SG11201701861RA (en) 2017-04-27
US9790235B2 (en) 2017-10-17
MX373341B (es) 2020-05-26
DK3193611T3 (da) 2021-05-10
MX2020005213A (es) 2020-08-20
EP3193611B1 (en) 2021-03-24
PT3193611T (pt) 2021-05-28
JP6556225B2 (ja) 2019-08-07
US10577380B2 (en) 2020-03-03
CA2961607C (en) 2023-03-28
PL3193611T3 (pl) 2021-10-04
US10253040B1 (en) 2019-04-09
CL2017000576A1 (es) 2017-12-01
US20160075720A1 (en) 2016-03-17
ECSP17023281A (es) 2017-06-30
JP2017529367A (ja) 2017-10-05
SG10201902326XA (en) 2019-04-29
KR102457848B1 (ko) 2022-10-25
RS62017B1 (sr) 2021-07-30
CY1124215T1 (el) 2022-05-27
US20190375762A1 (en) 2019-12-12
BR112017005266A2 (pt) 2017-12-12

Similar Documents

Publication Publication Date Title
JP7375072B2 (ja) Mk2阻害剤およびその使用
EP3080103B9 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
CN110494433B (zh) 布鲁顿酪氨酸激酶抑制剂
KR20210108433A (ko) 티에노피리디논 화합물
RU2827549C2 (ru) Соединения тиенопиридинона
HK1241225A1 (en) Mk2 inhibitors and uses thereof
HK1241225B (en) Mk2 inhibitors and uses thereof
EP4608401A2 (en) Mk2 inhibitors and uses thereof
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds
HK1229333A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333B (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 57/00

Ipc: C07D 495/14 (2006.01), A61K 31/551 (2006.01), A61P

B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2015, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: BRISTOL-MYERS SQUIBB COMPANY (US)